监测人体唾液中的米索硝唑：血浆监测的一种可能替代方法。
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.
作者信息
Workman P, Wiltshire C R, Plowman P N, Bleehen N M
出版信息
Br J Cancer. 1978 Dec;38(6):709-18. doi: 10.1038/bjc.1978.277.
Abstract
Concentrations of misonidazole and its O-demethylated metabolite Ro 05-9963 in the plasma and saliva of 10 patients with malignant disease have been determined. A good linear correlation was established between plasma and saliva misonidazole concentration, and salivary sampling was found to be suitable for the estimation of a number of pharmacokinetic parameters. Data are also presented for serial tumour cencentrations of misonidazole and Ro 05-9963 in 3 of the 10 patients. Monitoring of salivary misonidazole concentration appears to be a useful alternative to plasma monitoring, particularly for those patients in whom plasma sampling is unsuitable or impossible.
摘要
已测定10例恶性疾病患者血浆和唾液中米索硝唑及其O-去甲基代谢物Ro 05-9963的浓度。血浆和唾液中米索硝唑浓度之间建立了良好的线性相关性，并且发现唾液采样适用于估算多个药代动力学参数。还给出了10例患者中3例的米索硝唑和Ro 05-9963的系列肿瘤浓度数据。监测唾液中米索硝唑浓度似乎是血浆监测的一种有用替代方法，特别是对于那些血浆采样不合适或不可能的患者。
相似文献
1
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.监测人体唾液中的米索硝唑：血浆监测的一种可能替代方法。
Br J Cancer. 1978 Dec;38(6):709-18. doi: 10.1038/bjc.1978.277.
2
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.在小鼠肿瘤中测试乏氧细胞放射增敏剂时的药代动力学考量
Br J Cancer. 1979 Mar;39(3):310-20. doi: 10.1038/bjc.1979.55.
3
The penetration of misonidazole into spontaneous canine tumours.米索硝唑在犬自发性肿瘤中的渗透情况。
Br J Cancer. 1979 Aug;40(2):284-94. doi: 10.1038/bjc.1979.177.
4
Cytotoxicity of misonidazole in vivo under conditions of prolonged contact of drug with the tumour cells.在药物与肿瘤细胞长时间接触的条件下，米索硝唑在体内的细胞毒性。
Br J Radiol. 1979 Nov;52(623):893-6. doi: 10.1259/0007-1285-52-623-893.
5
[Assay of a radiation-sensitizer, misonidazole, by high-performance liquid chromatography].[用高效液相色谱法测定放射增敏剂米索硝唑]
Ann Pharm Fr. 1983 Feb;40(5):459-64.
6
Pharmacokinetic considerations of misonidazole in therapeutics.米索硝唑在治疗学中的药代动力学考量。
Hum Toxicol. 1984 Feb;3(1):29-36. doi: 10.1177/0960327184003001041.
7
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.苯巴比妥和苯妥英预处理对苯妥英在小鼠体内药代动力学及米索硝唑毒性的影响。
Br J Cancer. 1979 Sep;40(3):335-53. doi: 10.1038/bjc.1979.187.
8
Kinetic aspects of misonidazole and its major metabolite in radiotherapy.米索硝唑及其主要代谢物在放射治疗中的动力学研究
Hum Toxicol. 1985 Jul;4(4):425-34. doi: 10.1177/096032718500400409.
9
A serial study of the concentration of misonidazole in human tumors correlated with histologic structure.一项关于人肿瘤中米索硝唑浓度与组织结构相关性的系列研究。
Int J Radiat Oncol Biol Phys. 1981 Feb;7(2):197-203. doi: 10.1016/0360-3016(81)90437-5.
10
Plasma concentrations of misonidazole.米索硝唑的血浆浓度。
Strahlentherapie. 1980;156(10):714-8.
引用本文的文献
1
Saliva as a sampling source for the detection of leukemic fusion transcripts.唾液作为检测白血病融合转录本的采样来源。
J Transl Med. 2014 Nov 19;12:321. doi: 10.1186/s12967-014-0321-z.
2
Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring.烟酰胺在人体内的药代动力学：胃酸抑制的影响、直肠给药与口服给药的比较以及唾液用于药物监测的研究
Br J Cancer. 1996 Jul;74(1):16-21. doi: 10.1038/bjc.1996.309.
3
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.米索硝唑和去甲基米索硝唑在小鼠体内的药代动力学剂量依赖性及相关研究
Cancer Chemother Pharmacol. 1980;5(1):27-37. doi: 10.1007/BF00578559.
4
A rapid and specific semi-micro method involving high-pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.一种快速且特异的半微量方法，该方法涉及高压液相色谱法，用于测定血浆、唾液、血清、尿液和全血中的甲硝唑。
Br J Clin Pharmacol. 1980 May;9(5):528-9. doi: 10.1111/j.1365-2125.1980.tb05856.x.
5
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.苯妥英钠可缩短人体中缺氧细胞放射增敏剂米索硝唑的半衰期：对可能降低毒性的意义。
Br J Cancer. 1980 Feb;41(2):302-4. doi: 10.1038/bjc.1980.43.
6
Structure-pharmacokinetic relationships for misonidazole analogues in mice.米索硝唑类似物在小鼠体内的结构-药代动力学关系
Cancer Chemother Pharmacol. 1981;6(1):39-49. doi: 10.1007/BF00253009.
7
Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.硝基咪唑类药物和L-苯丙氨酸氮芥在乳腺腺癌16/C肿瘤中的分布。
Cancer Chemother Pharmacol. 1987;20(3):188-92. doi: 10.1007/BF00570482.
8
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.苯巴比妥和苯妥英预处理对苯妥英在小鼠体内药代动力学及米索硝唑毒性的影响。
Br J Cancer. 1979 Sep;40(3):335-53. doi: 10.1038/bjc.1979.187.
9
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.在小鼠肿瘤中测试乏氧细胞放射增敏剂时的药代动力学考量
Br J Cancer. 1979 Mar;39(3):310-20. doi: 10.1038/bjc.1979.55.
10
The penetration of misonidazole into spontaneous canine tumours.米索硝唑在犬自发性肿瘤中的渗透情况。
Br J Cancer. 1979 Aug;40(2):284-94. doi: 10.1038/bjc.1979.177.
本文引用的文献
1
[Chemistry of residual saliva of a single salivary gland].[单个唾液腺残余唾液的化学性质]
Helv Med Acta. 1957 Nov;24(5):600-21.
2
3
Application of salivary salicylate data to biopharmaceutical studies of salicylates.唾液水杨酸数据在水杨酸盐生物制药研究中的应用。
J Pharm Sci. 1972 Aug;61(8):1219-22. doi: 10.1002/jps.2600610810.
4
Comparison of human serum, parotid and mixed saliva levels of phenoxymethylpenicillin, ampicillin, cloxacillin and cephalexin.苯氧甲基青霉素、氨苄青霉素、氯唑西林和头孢氨苄在人血清、腮腺唾液及混合唾液中的水平比较。
Br J Pharmacol. 1971 Sep;43(1):242-7. doi: 10.1111/j.1476-5381.1971.tb07173.x.
5
Clearance and biologic half-life as indices of intrinsic hepatic metabolism.清除率和生物半衰期作为肝脏内在代谢的指标。
J Pharmacol Exp Ther. 1974 Oct;191(1):17-24.
6
Commentary: a physiological approach to hepatic drug clearance.述评：肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
7
Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology.收集混合唾液中各个成分的方法：与临床药理学的相关性。
Br J Clin Pharmacol. 1976 Apr;3(2):315-9. doi: 10.1111/j.1365-2125.1976.tb00609.x.
8
9
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.放射增敏剂Ro 07-0582的临床试验：多次给药的经验
Br J Cancer. 1977 May;35(5):567-79. doi: 10.1038/bjc.1977.90.
10
Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.2-硝基咪唑衍生物低氧细胞放射增敏剂RO-07-0582的临床I期研究
Radiology. 1977 Mar;122(3):801-4. doi: 10.1148/122.3.801.
Zotero 插件